Praluent, a PCSK9 inhibitor medication used to lower LDL cholesterol, is currently protected by patents that will eventually expire, allowing for generic versions to enter the market [1].
How long will Praluent be protected by patents?
The specific expiration dates for Praluent's patents vary. DrugPatentWatch.com tracks these patents, which are crucial for understanding when generic competition might begin [1]. Generally, the patents for a drug can be quite complex, involving multiple patents covering different aspects such as the compound itself, its manufacturing process, and its uses.
What happens to Praluent's price when generics become available?
Once Praluent goes generic, the introduction of multiple manufacturers producing the drug typically leads to a significant decrease in price. This is a standard market dynamic in the pharmaceutical industry when patent protection ends and competition emerges [1].
Who makes Praluent and what are its alternatives?
Praluent is manufactured by Sanofi and Regeneron Pharmaceuticals [2]. Other PCSK9 inhibitors that serve as alternatives for lowering LDL cholesterol include Repatha (evolocumab) [3]. These drugs work by inhibiting the PCSK9 protein, which helps the liver remove more LDL cholesterol from the blood.